The rapidly aging population and urbanization trends have triggered an increase in the global incidence of cancer. EnhancedBio Inc. was established to provide hope to cancer patients by novel anti-cancer therapeutics.
Our first pipeline is 'HPV siRNA therapeutics' treating various cancers caused by Human Papilloma Virus (HPV) infection. HPVs are small DNA viruses; some oncogenic ones can cause different types of cancer, namely cervical cancer, head & neck cancer, oral cancer, anal cancer, genital cancer and lung cancer. HPV-associated carcinogenesis provides a classical model system for RNA interference (RNAi) based cancer therapies, because the viral oncogenes causes cervical cancer are expressed only in cancerous cells. Previous studies on the development of therapeutic RNAi facilitated the advancement of therapeutic siRNAs and demonstrated its versatility by siRNA-mediated depletion of single or multiple cellular/viral targets. Sequence-specific gene silencing using RNAi shows promise as a novel therapeutic approach for the treatment of a variety of diseases that currently lack effective treatments. During the last several years, we have validated our final candidate of its efficacy in vitro and in vivo, for its potential off-target effects, and of the design of conventional therapies to be used in combination with siRNAs and their drug delivery vehicles. The pipeline was developed initially to solve unmet medical needs in 'Head & Neck cancer' treatment and the final HPV siRNA candidate is ready to apply phase 1 clinical trial. Another gene therapy pipelines for the novel onco-targets including PMVK and RRM2 gene are under development.
We have also successfully developed small molecular drug pipelines for another novel onco-targets including PTEN, PMVK and etc.
We have continued to build a strong patent portfolio by accumulating valuable intellectual property for the pipelines, which is essential in the creative economy. The company has built an IP infrastructure based on our portfolio, encompassing technology valuation, evergreening and patent dispute prevention strategies.
EnhancedBio will constantly strive to develop novel anti-cancer therapeutics that are well recognized in the global pharmaceutical market and will succeed in licensing-out international patents in near future. We will also continue to further strengthen our R&D capabilities as a global leader. We sincerely look forward to your continued interest and encouragement to Enhancedbio Inc.